PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Patients will receive RCD or PCD combination as induction treatment followed by rituximab or
velcade maintenance therapy, as the investigators try to compare the, very good partial
remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR +
partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the
research.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University